Summit Therapeutics PLC (SMMT)
Summit Therapeutics PLC (SMMT) is a NASDAQ-listed ADR, or depositary receipt, tied to the company’s underlying shares rather than an operating business of its own. The security reflects Summit Therapeutics PLC, which is classified in healthcare and biotechnology. In broad terms, the company is associated with drug development work, including research-stage and clinical-stage programs in therapeutic areas such as oncology. Because this is an ADR, investors are looking at a listed instrument that tracks the foreign issuer’s equity interest, not a separate product company. The classification details indicate a common stock depositary receipt on NASDAQ.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SMMT
|
$15.40
|
8.5% Upside
|
Fair
|
$28.75
|
102.6% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
July 23, 2026
|
-9.2x
|
20.3x
|
—
|
10.478 B
|
10.505 B
|
0.2%
|
16.8%
|
51.0
|
—
|
31.9%
|
